Logo image of ER7.DE

ERAMET (ER7.DE) Stock Fundamental Analysis

FRA:ER7 - Deutsche Boerse Ag - FR0000131757 - Common Stock

55.35  +0.75 (+1.37%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ER7. ER7 was compared to 39 industry peers in the Metals & Mining industry. While ER7 is still in line with the averages on profitability rating, there are concerns on its financial health. ER7 is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

ER7 had negative earnings in the past year.
In the past year ER7 has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: ER7 reported negative net income in multiple years.
ER7 had a positive operating cash flow in each of the past 5 years.
ER7.DE Yearly Net Income VS EBIT VS OCF VS FCFER7.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M -500M 1B

1.2 Ratios

With a Return On Assets value of -0.44%, ER7 perfoms like the industry average, outperforming 47.22% of the companies in the same industry.
ER7's Return On Equity of -1.88% is in line compared to the rest of the industry. ER7 outperforms 44.44% of its industry peers.
The Return On Invested Capital of ER7 (0.95%) is worse than 72.22% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ER7 is in line with the industry average of 6.18%.
The last Return On Invested Capital (0.95%) for ER7 is well below the 3 year average (7.17%), which needs to be investigated, but indicates that ER7 had better years and this may not be a problem.
Industry RankSector Rank
ROA -0.44%
ROE -1.88%
ROIC 0.95%
ROA(3y)5.62%
ROA(5y)0.67%
ROE(3y)25.94%
ROE(5y)-4.74%
ROIC(3y)7.17%
ROIC(5y)5.45%
ER7.DE Yearly ROA, ROE, ROICER7.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 -60 -80

1.3 Margins

In the last couple of years the Profit Margin of ER7 has grown nicely.
ER7 has a Operating Margin of 3.68%. This is comparable to the rest of the industry: ER7 outperforms 44.44% of its industry peers.
In the last couple of years the Operating Margin of ER7 has declined.
ER7 has a better Gross Margin (66.44%) than 94.44% of its industry peers.
In the last couple of years the Gross Margin of ER7 has grown nicely.
Industry RankSector Rank
OM 3.68%
PM (TTM) N/A
GM 66.44%
OM growth 3Y-25.05%
OM growth 5Y-24.15%
PM growth 3YN/A
PM growth 5Y18.7%
GM growth 3Y-1.38%
GM growth 5Y19.66%
ER7.DE Yearly Profit, Operating, Gross MarginsER7.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 60

More info and screens

3

2. Health

2.1 Basic Checks

ER7 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ER7 remains at a similar level compared to 1 year ago.
The number of shares outstanding for ER7 has been increased compared to 5 years ago.
Compared to 1 year ago, ER7 has a worse debt to assets ratio.
ER7.DE Yearly Shares OutstandingER7.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
ER7.DE Yearly Total Debt VS Total AssetsER7.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B

2.2 Solvency

Based on the Altman-Z score of 1.29, we must say that ER7 is in the distress zone and has some risk of bankruptcy.
ER7 has a Altman-Z score of 1.29. This is in the lower half of the industry: ER7 underperforms 69.44% of its industry peers.
A Debt/Equity ratio of 1.27 is on the high side and indicates that ER7 has dependencies on debt financing.
ER7 has a Debt to Equity ratio of 1.27. This is amonst the worse of the industry: ER7 underperforms 91.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.27
Debt/FCF N/A
Altman-Z 1.29
ROIC/WACC0.13
WACC7.23%
ER7.DE Yearly LT Debt VS Equity VS FCFER7.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B 2B

2.3 Liquidity

ER7 has a Current Ratio of 2.08. This indicates that ER7 is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.08, ER7 is in the better half of the industry, outperforming 72.22% of the companies in the same industry.
ER7 has a Quick Ratio of 1.66. This is a normal value and indicates that ER7 is financially healthy and should not expect problems in meeting its short term obligations.
ER7 has a Quick ratio of 1.66. This is in the better half of the industry: ER7 outperforms 77.78% of its industry peers.
Industry RankSector Rank
Current Ratio 2.08
Quick Ratio 1.66
ER7.DE Yearly Current Assets VS Current LiabilitesER7.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for ER7 have decreased strongly by -119.24% in the last year.
The Earnings Per Share has been growing by 15.49% on average over the past years. This is quite good.
Looking at the last year, ER7 shows a very negative growth in Revenue. The Revenue has decreased by -22.19% in the last year.
ER7 shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.69% yearly.
EPS 1Y (TTM)-119.24%
EPS 3YN/A
EPS 5Y15.49%
EPS Q2Q%-142.48%
Revenue 1Y (TTM)-22.19%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.69%
Sales Q2Q%-9.48%

3.2 Future

ER7 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.18% yearly.
The Revenue is expected to grow by 4.03% on average over the next years.
EPS Next Y4.12%
EPS Next 2Y25.48%
EPS Next 3Y35.18%
EPS Next 5YN/A
Revenue Next Year-9.63%
Revenue Next 2Y0.45%
Revenue Next 3Y4.03%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ER7.DE Yearly Revenue VS EstimatesER7.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1B 2B 3B 4B 5B
ER7.DE Yearly EPS VS EstimatesER7.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 10 20 30

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

ER7 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 5.40, the valuation of ER7 can be described as very cheap.
88.89% of the companies in the same industry are more expensive than ER7, based on the Price/Forward Earnings ratio.
ER7 is valuated cheaply when we compare the Price/Forward Earnings ratio to 24.11, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 5.4
ER7.DE Price Earnings VS Forward Price EarningsER7.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ER7 indicates a rather cheap valuation: ER7 is cheaper than 88.89% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.99
ER7.DE Per share dataER7.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60 80 100

4.3 Compensation for Growth

ER7's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as ER7's earnings are expected to grow with 35.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.48%
EPS Next 3Y35.18%

More info and screens

3

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 2.70%, ER7 has a reasonable but not impressive dividend return.
ER7's Dividend Yield is a higher than the industry average which is at 3.85.
Compared to an average S&P500 Dividend Yield of 2.33, ER7 has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.7%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
ER7.DE Yearly Dividends per shareER7.DE Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 1 2 3

5.3 Sustainability

DP0%
EPS Next 2Y25.48%
EPS Next 3Y35.18%
ER7.DE Yearly Income VS Free CF VS DividendER7.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M -500M

More info and screens

ERAMET

FRA:ER7 (1/16/2025, 7:00:00 PM)

55.35

+0.75 (+1.37%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)10-24 2024-10-24
Earnings (Next)02-19 2025-02-19/amc
Inst Owners11.49%
Inst Owner ChangeN/A
Ins Owners0.11%
Ins Owner ChangeN/A
Market Cap1.59B
Analysts80
Price Target85.51 (54.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.7%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.8%
PT rev (3m)-34.74%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-42.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-3.85%
Revenue NY rev (3m)-14.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.4
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B 1
P/tB 1.39
EV/EBITDA 3.99
EPS(TTM)-1.07
EYN/A
EPS(NY)10.25
Fwd EY18.51%
FCF(TTM)-22.84
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS107.75
BVpS55.39
TBVpS39.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.44%
ROE -1.88%
ROCE 2.14%
ROIC 0.95%
ROICexc 1.34%
ROICexgc 1.52%
OM 3.68%
PM (TTM) N/A
GM 66.44%
FCFM N/A
ROA(3y)5.62%
ROA(5y)0.67%
ROE(3y)25.94%
ROE(5y)-4.74%
ROIC(3y)7.17%
ROIC(5y)5.45%
ROICexc(3y)10.55%
ROICexc(5y)7.93%
ROICexgc(3y)12.48%
ROICexgc(5y)9.35%
ROCE(3y)16.5%
ROCE(5y)12.5%
ROICexcg growth 3Y-19.97%
ROICexcg growth 5Y-24.81%
ROICexc growth 3Y-19.75%
ROICexc growth 5Y-24.91%
OM growth 3Y-25.05%
OM growth 5Y-24.15%
PM growth 3YN/A
PM growth 5Y18.7%
GM growth 3Y-1.38%
GM growth 5Y19.66%
F-Score3
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 1.27
Debt/FCF N/A
Debt/EBITDA 4.61
Cap/Depr 202.16%
Cap/Sales 21.14%
Interest Coverage 0.66
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.08
Quick Ratio 1.66
Altman-Z 1.29
F-Score3
WACC7.23%
ROIC/WACC0.13
Cap/Depr(3y)182%
Cap/Depr(5y)147.41%
Cap/Sales(3y)13.6%
Cap/Sales(5y)13.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-119.24%
EPS 3YN/A
EPS 5Y15.49%
EPS Q2Q%-142.48%
EPS Next Y4.12%
EPS Next 2Y25.48%
EPS Next 3Y35.18%
EPS Next 5YN/A
Revenue 1Y (TTM)-22.19%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.69%
Sales Q2Q%-9.48%
Revenue Next Year-9.63%
Revenue Next 2Y0.45%
Revenue Next 3Y4.03%
Revenue Next 5YN/A
EBIT growth 1Y-72.6%
EBIT growth 3Y-21.15%
EBIT growth 5Y-26.19%
EBIT Next Year181.88%
EBIT Next 3Y68.43%
EBIT Next 5YN/A
FCF growth 1Y-267.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-100.24%
OCF growth 3Y-12.93%
OCF growth 5Y-14.13%